Algert Global LLC Dynavax Technologies Corp Transaction History

Algert Global LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.73 - $12.58 $134,082 - $157,199	12,496 New	12,496 $140,000
Q2 2022 Aug 15, 2022	SELL	$7.45 - $12.83 $421,074 - $725,151	-56,520 Reduced 84.75%	10,167 $128,000
Q1 2022 May 16, 2022	BUY	$9.75 - $14.44 $415,369 - $615,172	42,602 Added 176.88%	66,687 $723,000
Q4 2021 Feb 14, 2022	SELL	$13.17 - $20.94 $233,346 - $371,014	-17,718 Reduced 42.38%	24,085 $339,000
Q3 2021 Nov 15, 2021	BUY	$9.16 - $19.83 $382,915 - $828,953	41,803 New	41,803 $803,000

273

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.6B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.